NEWS RELEASE

Biosensors Receives CE Mark Approval for BioMatrix Flex™

22 January 2010 – Biosensors International Group, Ltd. has received CE Mark approval for a new version of its BioMatrix™ drug-eluting stent system, the BioMatrix Flex™.

BioMatrix™ was originally launched in Europe in April 2008, where its unique combination of a Biosensors-developed abluminal biodegradable polymer and proprietary limus drug, Biolimus A9™, rapidly proved successful. The BioMatrix Flex also incorporates the Company's abluminal biodegradable polymer and Biolimus A9™. In just two years, the Company has received CE Mark approvals for the first version of its BioMatrix drug-eluting stent (January 2008), its smaller-diameter (2.25 mm) version (March 2009) and now the BioMatrix Flex.

Mike Kleine, President and CEO, commented, "We are extremely pleased to receive approval of BioMatrix Flex. This approval once again demonstrates our commitment to innovation as well as our ability to accelerate the pace of change. We are excited to offer yet another product to improve patients' lives."

The BioMatrix Flex™ stent will be made available for physicians' use over the coming months.

-Ends-

For further information, please contact:

Susanne Meis: s.meis@biosensors.com +49 171 8918919

Richard Kenyon: richard@rkpr.co.uk +44 7831 569940

About Biosensors International Group, Ltd
Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents and has developed a pipeline of next-

generation products that are set to gain market share from traditional therapies such as conventional drug-eluting stents, bare-metal stents and open-heart surgery. It has two separate drug-eluting stent programs, BioMatrix™ and BioFreedom™, a completely polymer-free drug-eluting stent.

About the BioMatrix™ Stent Family
BioMatrix™ offers the unique combination of an innovative anti-restenotic drug, Biolimus A9™, a biodegradable poly-lactic acid polymer (PLA), and an advanced, highly flexible stent designed for enhanced deliverability.

BA9™ was designed specifically for use in drug-eluting stent systems. In addition to effective immunosuppressive and anti-inflammatory properties, the drug has a higher lipophilic and hydrophobic profile than other limus analogs, enabling rapid absorption of the drug into the targeted tissue and reduced systemic exposure. Precision automated coating ensures the PLA and drug combination is applied only to the abluminal (outer) surface of the stent. The PLA fully degrades into water and carbon dioxide over a six to nine month period as the drug elutes, ultimately leaving in place a biocompatible stent surface.